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The increasing incidence of antibiotic-resistant bacterial infections is creating a global public 
health threat. Since conventional antibiotic drug discovery has failed to keep pace with the rise of 
resistance, a growing need exists to develop novel antibacterial methodologies. Replication-
competent bacteriophages have been utilized in a limited fashion to treat bacterial infections. 
However, this approach can result in the release of harmful endotoxins, leading to untoward side 
effects. Here, we engineer bacterial phagemids to express antimicrobial peptides (AMPs) and 
protein toxins that disrupt intracellular processes, leading to rapid, non-lytic bacterial death. We 
show that this approach is highly modular, enabling one to readily alter the number and type of 
AMPs and toxins encoded by the phagemids. Furthermore, we demonstrate the effectiveness of 
engineered phagemids in an in vivo murine peritonitis infection model. This work shows that 
targeted, engineered phagemid therapy can serve as a viable, non-antibiotic means to treat 
bacterial infections, while avoiding the health issues inherent to lytic and replicative 
bacteriophage use. 
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TEXT  
Antibiotic-resistant bacterial infections are an increasing concern in clinical and non-clinical 
settings1. Current first-line treatments rely upon the administration of small-molecule antibiotics 
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to induce bacterial cell death. It is widely acknowledged that these broad-spectrum treatments 
disrupt the patient’s normal microflora, allowing resistant bacteria and fungal pathogens to take 
advantage of vacated niches2. Therefore, a renewed interest has emerged for the use of targeted 
bacteriophage therapy to combat bacterial infections. Bacteriophages offer several distinct 
advantages over traditional antibiotic treatment, including high bacterial target specificity and 
reduced collateral damage to the host microbiota. They also have the potential to deliver 
synthetic gene networks, which can be designed to disrupt bacterial structures and processes 
through the expression of antibacterial or sensitizing genes3. Historically, phage therapy has 
relied upon lytic bacteriophages, which cause bacterial cell death through the rupture of the 
bacterial cell membrane. However, bacterial lysis results in the release of expressed proteins and 
endotoxins into the surrounding environment4. This in turn can lead to detrimental side effects, 
ranging from diarrhea to sepsis and even death. 
 
Previous efforts have attempted to overcome this by using lysogenic bacteriophages that, in 
contrast to their lytic counterparts, secrete mature bacteriophage particles without causing 
cellular lysis. Although lysogenic bacteriophages have been engineered to serve as adjuvants to 
antibiotics by overexpressing sensitizing proteins5, their dependence upon antibiotics makes 
them inherently non-lethal and ineffective on their own. Most importantly, lysogenic 
bacteriophage genomes become less reliable over time due to fluctuations in genome copy 
number as they become packaged into viral particles. Repeated infection-reinfection cycles can 
also render infected bacteria resistant to further bacteriophage infection as the target cell tries to 
escape superinfection6, reducing the effect of repeated treatment. These limitations diminish the 
effectiveness of bacteriophage therapies as a viable treatment strategy. 
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In the present study, we engineered a modular bacterial phagemid system, which expresses a 
variety of non-lytic antimicrobial peptides (AMPs) and toxin proteins, to address the rising need 
for non-traditional, antibacterial treatment solutions. Phagemids, which employ bacteriophage 
proteins but selectively package a synthetic plasmid, provide a marked benefit over standard 
bacteriophage therapies, lytic and lysogenic alike. This system limits the serious side effects 
linked to lytic bacteriophage approaches and improves upon lysogenic therapies by allowing for 
the direct delivery of specific high-copy plasmids to target cells in a single round of infection, 
ensuring consistent network expression levels and long-term stability (Supplemental Figure 1).  
 
Our phagemid system relies upon the expression of two plasmids: the first plasmid carries a 
bacteriophage-packaging signal and the desired antibacterial gene network, while the second 
plasmid contains a phagemid helper system7, which generates the bacteriophage proteins 
required for particle assembly but is not packaged itself. Together, these plasmids produce 
bacteriophage particles that selectively package an engineered plasmid harboring a synthetic 
gene network and a stable origin of replication rather than the bacteriophage genome. This 
approach allows for sustained network expression and reduces the formation of bacteriophage 
resistance by avoiding bacteriophage particle replication and superinfection in target cells. 
 
We designed this phagemid system to be highly modular by employing the previously 
developed plug-and-play cloning platform developed by Litcofsky et al8. This platform employs 
 5 
a high-copy plasmid that contains a large multiple cloning site (MCS) into which we inserted a 
range of engineered antibacterial networks along with the F1 origin of replication, which serves 
as the packaging signal for the M13 bacteriophage9. The fully constructed phagemid plasmid was 
then transformed into a production strain, carrying the M13cp phagemid helper plasmid. 
Phagemid particles produced by this strain were then used for single-round infection of the target 
Escherichia coli (E. coli) cells, leading to non-lytic bacterial cell death (Figure 1).  
 
In order to initially screen AMPs that cause non-lytic bacterial cell death, we developed a test 
network expressing two tandem copies of the antibacterial gene of interest under regulation of 
the tetR-repressed PLtetO promoter. Importantly, this design allows for activation of antibacterial 
networks in target wildtype (WT) strains, but represses these networks in tetR (Tet repressor 
protein) expressing test and production strains. Synthetic design of the ribosome binding site10 
(RBS) for each antibacterial gene allowed for the independent tuning of expression levels. Five 
AMPs − cecropin PR-3911, apidaecin Ia12, buforin II13, dermaseptin14, and pleurocidin15 − were 
selected for their reported ability to rapidly disrupt intracellular processes and induce non-lytic 
bacterial death16 (Supplemental Table 1). Together with their PLtetO promoter, synthetic RBS, and 
terminator, these AMP genes were transformed into the test strain, mgpro, and their efficacy for 
bacterial death was measured upon anhydrotetracycline (aTc) induced expression (Figure 2A). 
We found that cecropin PR-39 (cecropin) and apidaecin Ia (apidaecin) were effective at inducing 
bacterial cell death; cecropin inhibits septum formation as well as DNA and protein production, 
while apidaecin inhibits the enzyme DnaK and binds to bacterial lipopolysaccharide. The 
remaining AMPs tested did not induce bacterial cell death, possibly due to post-translational 
modifications or microenvironmental differences with previous studies that our growth 
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conditions did not replicate. Based on these results, we decided to use cecropin and apidaecin for 
subsequent experiments.  
 
To examine the efficacy of cecropin and apidaecin as antibacterial therapeutics, we introduced 
these AMP expression networks into the phagemid system. After transforming the system into 
the phagemid production strain (DH5αpro) carrying the M13 helper plasmid, we collected the 
purified phagemid particles and screened them against the target bacterial strain. Additionally, 
we introduced these antibacterial networks into the M13 bacteriophage system in order to 
compare their antibacterial effects. We found that treatment with phagemid particles harboring 
networks expressing cecropin or apidaecin reduced bacterial cell viability by 2−3 orders of 
magnitude (Figure 2B). This effect persisted for several hours post infection. In contrast, target 
cells infected with bacteriophage particles carrying the same AMP expression networks failed to 
produce the same level of bacterial death. Although initial killing was observed, the cell 
population recovered after approximately four hours of infection, likely due to inconsistent 
network expression.  
 
In addition to the phagemid’s ability to sustain bacterial death, we tested whether this approach 
induced resistance in target cells at a level comparable to that seen with bacteriophage therapy17. 
Target bacteria were first infected with either phagemid or bacteriophage particles expressing the 
cecropin AMP network and then subsequently reinfected with phagemid or bacteriophage 
particles expressing a GFP network (Figure 3A). Bacteria first infected with bacteriophage 
particles expressing the cecropin network were found to be resistant to a repeated bacteriophage 
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infection with a GFP-expressing network (Figure 3B). In contrast, bacteria first infected with 
phagemid particles carrying the cecropin network maintained their ability to be reinfected with a 
second round of GFP-expressing phagemid particles. These results highlight both the 
unreliability of bacteriophage therapy and the increased risk of resistance formation, which are 
avoided or reduced through the use of phagemids.   
 
After distinguishing phagemids as a superior therapy option over bacteriophages, we next 
studied the modular nature of the phagemid system. Since cecropin and apidaecin target distinct 
intracellular processes, we hypothesized that simultaneous targeting could potentially increase 
phagemid-induced bacterial cell death. To test this hypothesis, we created three combination 
networks expressing both AMPs together (Figure 4A). Two of these networks (designated ϕI and 
ϕII) expressed a single copy of each AMP in varying order, while a third network (designated ϕIII) 
expressed two copies of each AMP with a PLtetO promoter driving each set. The combined 
phagemid networks had an enhanced effect upon the target bacteria, with the ϕIII network 
producing a 3.5 log reduction in bacterial cell viability. 
 
To potentially increase the antibacterial efficacy of the phagemid treatment, we next chose to 
evaluate the effects of three bacterial toxins – Ccdb, YeeV’ and ParE – by introducing networks 
expressing the toxin genes into the modular ϕIII phagemid platform. The first toxin, CcdB, is a 
topoisomerase inhibitor that interferes with DNA gyrase and results in the breakdown of 
bacterial DNA18-20, leading to cell death. YeeV is a toxin that inhibits cellular division by 
targeting two cytoskeletal proteins, FtsZ and MreB21; however, this dual inhibition causes cells to 
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balloon and lyse, which is undesirable for our purposes. Sole inhibition of FtsZ can be 
accomplished by expression of a modified version of the YeeV protein truncated at the C 
terminus by 52 residues (designated YeeV’), which results in filamented cells that do not lyse21. 
The last toxin, ParE, acts by halting the F1* formation from both chromosomal and plasmid 
DNA replication origins by inhibiting bacterial gyrase, causing filamentation and cell death22. 
Infection of target cells with phagemid particles carrying the combined AMP-CcdB network 
resulted in increased bacterial cell death, leading to a 4.0 log reduction in bacterial cell viability 
within the first two hours (Figure 4B). The addition of yeeV’ resulted in bacterial cell death 
comparable to that of ϕIII alone, while the addition of parE led to reduced killing, possibly due to 
direct interaction with our phagemid plasmid’s ability to replicate.  
 
With these results, a final synthetic network employing the most productive toxin was 
generated. This construct, designated ϕIV, overexpressed ccdB through tandem gene expression 
in order to maximize its antibacterial effect and was combined with the ϕIII AMP network. 
Purified phagemid particles were then tested against the target bacteria for induced bacterial cell 
death (Figure 4C). Expression of ϕIV provided almost an order of magnitude of increased 
bacterial cell death compared to ϕIII alone. This difference was further enhanced by increasing 
the virion particle dose, resulting in over 5.0 log reduction in bacterial survival after 6 hours of 
exposure to the ϕIV network (Figure 4D). Taken altogether, our screen identified that the 
combined phagemid-based expression of two copies of cecropin PR-39, apidaecin Ia, and ccdB 
genes resulted in robust killing of target E. coli bacteria. 
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We next tested the in vivo efficacy of our system by employing a murine model for E. coli 
peritonitis23. Seven-week-old C57Bl/6 female mice were administered 106 colony forming units 
(CFUs) of the target bacteria via intraperitoneal (IP) injection. After 1 hour, mice were treated 
with IP injections of phagemids expressing the ϕIV antibacterial-toxin network (Figure 5A). Mice 
were either not treated, injected with phagemid particles that do not express any genes (vehicle), 
or injected with phagemid particles containing the ϕIV network (Figure 5B). Mice given the ϕIV 
phagemid treatment had an average survival rate of 80% over the course of the experiment, 
compared to 27% survival in the untreated group, an increase that was statistically significant 
(p=0.003). The vehicle group experienced an improved survival of 58%, which was not 
statistically significant when compared to the untreated group (p=0.08). This effect was not 
observed in vitro (Supplemental Figure 2), suggesting that the increased survival was due to 
interactions with the host. A survival advantage provided by phage particles has been previously 
reported24 and may be associated with type I interferon and other proinflammatory gene 
induction upon exposure to phage capsid proteins. This proinflammatory effect is beneficial for 
treatment of bacterial infections, as phagemid particles prime the host immune system against 
unwanted bacteria. Taken together, our results show that engineered phagemids can effectively 
target and produce highly effective non-lytic killing of E. coli in vitro and in vivo, without the 
use of antibiotics.  
 
In this work, we developed a synthetic biology platform to produce non-lytic, bacterial cellular 
death without reliance upon traditional antibiotics. By designing and applying phagemid 
constructs containing selected AMPs, alone or in combination with bacterial toxins, we were 
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able to develop an approach that achieved over a 5.0 log reduction in bacterial cell viability in 
vitro and resulted in over 80% survival in a virulent mouse model of peritonitis. While the 
approach presented here relies upon the well-characterized M13 bacteriophage for phagemid 
production, similar systems can be produced using alternative bacteriophage systems to expand 
the repertoire of targetable bacteria. The modular nature of this system allows for the 
replacement and addition of individual components or whole networks within the engineered 
phagemid for the targeting of specific bacteria. When a packaging signal becomes characterized 
for a desired bacteriophage, it could be swapped with the F1 origin of replication in our synthetic 
antibacterial phagemid plasmid and cloned into a production strain that expresses the proper 
phage proteins. This enables production of both targeted and broad-spectrum antibacterial 
treatments, depending upon bacteriophage selection. While some toxins tested here had little 
effect on the target E. coli strain, the selected toxins have a broad-range activity across many 
bacterial species18-22, 25. Additionally, since our choices for antibacterial peptides are broad 
spectrum11-12, this system should provide a plug-and-play therapeutic that can be readily modified 
to suit its target and will therefore function in many target bacteria. Due to the stable nature of 
phagemids and decreased likelihood of resistance formation through superinfection, our system 
provides a marked advantage for targeting bacterial infections over current bacteriophage 
techniques. 
 
With recent discoveries highlighting the benefits and importance of healthy bacterial 
microbiomes26-27 as well as the rapid rise in antibiotic resistance, targeted therapies such as this, 
which do not rely on antibiotics, could provide an invaluable tool for treating bacterial infections 
and reducing the prevalence of antibiotic-resistant bacterial strains without producing collateral 
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damage in the commensal bacterial population. The decreasing cost of DNA synthesis 
technologies over the past decade28 and low cost of phagemid production should allow this 
platform to provide inexpensive and effective therapy options for bacterial infections in settings 
such as hospitals, where growing bacterial resistances and healthcare costs are becoming more of 
a problem29.  
 
FIGURES  
Figure 1. Overview of antibacterial phagemid construction. Phagemid plasmids, which carry an 
engineered antibacterial network, bacteriophage-packaging signal, and high-copy origin of 
replication, are first transformed into a production strain harboring a helper plasmid. Next, 
secreted phagemid particles are isolated from the production strain and purified. Resulting 
engineered phagemid particles are then used to infect target bacteria, causing expression of 
antibacterial proteins, which inhibit intracellular processes and cause non-lytic bacterial death. 
 
Figure 2. Testing antibacterial peptide candidates in test and phagemid networks. (A) Five 
antibacterial networks, expressing cecropin, apidaecin, buforin II, dermaseptin, or pleurocidin 
genes, were cloned into the testing strain, mgpro, and tested for their ability to cause bacterial 
cell death following induction with 100 ng/mL anhydrotetracycline (aTc), which relieves the 
inhibition of the PLtetO promoter by tetR. (B) Antibacterial networks expressing either cecropin or 
apidaecin networks were introduced into phagemid and bacteriophage plasmids, and the resulting 
particles were tested against EMG2 E. coli for their ability to cause non-lytic bacterial death.  
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Figure 3. Bacteriophage resistance determination for phagemid and bacteriophage therapies. (A) 
EMG2 E. coli were infected with either bacteriophage or phagemid particles carrying the 
cecropin antibacterial network. Six hours post infection these cells were monitored for network 
functionality and diluted overnight. The following day a secondary infection of either 
bacteriophage or phagemid particles carrying a GFP expression network was administered. 
These cells, including an uninfected control, were then monitored for GFP expression 6 hours 
post infection. (B) Infection data from the primary infection with phagemid or bacteriophage 
particles carrying the cecropin network showed expected bacterial death. Reinfection data from 
the secondary infection with phagemid or bacteriophage particles carrying a GFP network show 
bacteriophage resistance formation in samples exposed to bacteriophage but not phagemid 
particles.  
 
Figure 4. Modulation of AMP networks and enhancement by toxin networks. (A) Phagemids 
carrying synthetic networks that express combinations of cecropin and apidaecin antibacterial 
peptides were tested against EMG2 E. coli for their ability to cause bacterial death. These 
phagemid networks were designated ϕI, ϕII, and ϕIII respectively. (B) Three toxin networks, 
expressing ccdB, yeeV’, or parE genes were designed under regulation of the PLTetO promoter. 
These networks were cloned into the MCS of the ϕIII plasmid, and purified particles were 
screened against EMG2 E. coli for possible synergy with cecropin and apidaecin networks. 
Purified phagemid particles were tested alongside ϕIII particles for induction of bacterial death. 
(C) An overexpressing ccdB network was cloned into the MCS of the ϕIII plasmid. Purified 
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phagemid particles were screened against EMG2 E. coli for their ability to cause non-lytic 
bacterial death. (D) Various final concentrations of ϕIII and ϕIV phagemid particles were tested 
against target EMG2 bacteria. Bacterial cell viability was assessed 6 hours post infection.  
 
Figure 5. Murine peritonitis infection model with ϕIV expressing phagemid particles. (A) 
Overview of murine model for bacterial peritoneal infection with EMG2 E. coli bacteria and 
subsequent phagemid treatment. (B) Survival data for murine infection model with phagemid 
treatments and controls. Mice were divided into three groups: untreated (n=22), vehicle only 
(n=12), and ϕIV (n=10). Data were obtained from two separate experiments and significance was 
determined by a Mantel-Cox test. 
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